44th Annual J.P. Morgan Healthcare Conference January 12, 2026 Bob Ragusa, Chief Executive Officer Josh Ofman, President 1 This presentation contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," "would," or "will," the negative of these terms, and other comparable terminology. These forward-looking stat ...

Financial Performance - Q3 Fiscal Year 2026 total sales reached $706 million, exceeding the high-end guidance [8] - Q3 Fiscal Year 2026 earnings per share (EPS) were $2.79, surpassing the high-end guidance [8] - Q3 Fiscal Year 2026 income from operations was $114.8 million, also exceeding the high-end guidance [8] - Q3 Fiscal Year 2026 same-store sales (SSS) increased by 5.7% [8] - The company has experienced over a decade of strong sales growth, with Q3 Fiscal Year 2026 TTM (trailing twelve months) total sales reaching $2169 million [19] - Q3 Fiscal Year 2026 GAAP Earnings Per Share is $2.79, with 15% Growth vs LY[16] Strategic Initiatives - The company is focused on new store growth, with a target of 15% new store growth in Fiscal Year 2026 [26] - New stores are expected to have first-year net sales of approximately $3.2 million and a total net investment of around $1.7 million, resulting in a cash-on-cash return of approximately 53% and a payback period of about 1.8 years [24] - The company estimates a total addressable market (TAM) of approximately $58 billion and a potential for 1,200 stores in the U S [28] Margin and Exclusive Brands - The company's Q3 Fiscal Year 2026 YTD merchandise margin growth is estimated to have expanded by 790 basis points [54] - Exclusive brands penetration reached 41.1% in Q3 Fiscal Year 2026 YTD, enhancing margins by approximately 1,000 basis points compared to third-party brands [56] - Q3 Exclusive Brands Penetration % is 41.5%, +240bps vs LY[60]

Ascendis Pharma A/S J.P. Morgan Healthcare Conference San Francisco January 2026 This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which w ...

1 Forward-Looking Statements All statements other than historical facts contained in this presentation, including statements regarding the Company's future financial results and position, business policy and plans, objectives and expectations of management for future operations and capital allocation expectations, are forward-looking statements that are subject to material risks and uncertainties. The words "believe," "may," "could," "plans," "estimate," "expects," "continue," "anticipate," "intend," "expec ...

Krispy Kreme, Inc. ICR CONFERENCE 2026 JANUARY 12, 2026 Krispy Kreme | ICR Conference 2026 1 Cautionary Note Regarding Forward-Looking Statements Certain information included in this presentation and discussed on the webcast that this presentation accompanies are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with relation to Krispy Kreme, Inc.'s (the "Company") turnaround plan, refranchising transactions, business, prospects, future plans an ...

Transaction Announcement January 12, 2026 #FD8103 #005595 #FFD105 #394B5D #38AC49 #FD8103 #394B5D Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements under the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, Section 27A of the Securities Act of 1933 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and often can be identified by th ...

Exhibit 99 Investor Presentation ICR Conference 2026 January 12, 2026 Hamilton Beach Forward-Looking Statements · Core Consumer market is North America (U.S., Canada, Mexico, Latin America) · Increasing focus of the Premium small kitchen appliance market · Growing presence in global Commercial kitchen and hotel amenities markets · Developing global Home Healthcare solutions business Hamilton Beach OTUS Powerful Brand Portfolio Best Hamilton Beach Health Hamilton Beac NUMIL Flagship brand Hamilton Beach is a ...

#005595 #FFD105 #394B5D #38AC49 #FD8103 #394B5D Transaction Announcement January 12, 2026 #FD8103 Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements under the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, Section 27A of the Securities Act of 1933 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and often can be identified by th ...

Investor Presentation January 2026 Disclaimers Forward-Looking Statements This presentation includes express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management ...

1 Forward-Looking Statements This presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements, express or implied, related to Cytokinetics' research and development activities; clinical trial ini ...